These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6755560)

  • 81. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report.
    Renshaw PF; Daniels S; Lundahl LH; Rogers V; Lukas SE
    Psychopharmacology (Berl); 1999 Feb; 142(2):132-8. PubMed ID: 10102764
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pharmacokinetics of 14C CDP-choline.
    Dinsdale JR; Griffiths GK; Rowlands C; Castelló J; Ortiz JA; Maddock J; Aylward M
    Arzneimittelforschung; 1983; 33(7A):1066-70. PubMed ID: 6412727
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effect of Donepezil on Cognitive Deficits Associated With Electroconvulsive Therapy: A Randomized Triple-blind Clinical Trial.
    Shams-Alizadeh N; Maroufi A; Sofla AQC; Ghaderi E; Hassanzadeh K
    Clin Neuropharmacol; 2019; 42(2):27-31. PubMed ID: 30875343
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia.
    Kakihana M; Fukuda N; Suno M; Nagaoka A
    Stroke; 1988 Feb; 19(2):217-22. PubMed ID: 3344538
    [TBL] [Abstract][Full Text] [Related]  

  • 85. CDP-choline, but not cytidine, protects hippocampal CA1 neurones in the gerbil following transient forebrain ischaemia.
    Grieb P; Gadamski R; Wojda R; Janisz M
    Folia Neuropathol; 2001; 39(3):141-5. PubMed ID: 11770124
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Subjective side effects during electroconvulsive therapy.
    Devanand DP; Fitzsimons L; Prudic J; Sackeim HA
    Convuls Ther; 1995 Dec; 11(4):232-40. PubMed ID: 8919573
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Study on the protection of CDP-choline against nicotine intoxication.
    Grau T; Romero A; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1983; 33(7A):1025-6. PubMed ID: 6684456
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline.
    Agut J; Font E; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1983; 33(7A):1048-50. PubMed ID: 6684464
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The influence of cytidine on the endogenous pool of CDP-choline, CDP-ethanolamine, and CMP of the rat brain.
    Trovarelli G; Palmerini CA; Floridi A; Piccinin GL; Porcellati G
    Neurochem Res; 1984 Jan; 9(1):73-9. PubMed ID: 6717731
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Improvement in verbal memory performance in depressed in-patients after treatment with electroconvulsive therapy.
    Biedermann SV; Bumb JM; Demirakca T; Ende G; Sartorius A
    Acta Psychiatr Scand; 2016 Dec; 134(6):461-468. PubMed ID: 27658720
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A glutamatergic model of ECT-induced memory dysfunction.
    Chamberlin E; Tsai GE
    Harv Rev Psychiatry; 1998; 5(6):307-17. PubMed ID: 9559349
    [TBL] [Abstract][Full Text] [Related]  

  • 92. CDP-choline in the treatment of chronic cerebrovasculopathies.
    Piccoli F; Battistini N; Carbonin P; Currò Dossi B; Fiori L; La Bella V; Megna G; Salvioli G; Fioravanti M
    Arch Gerontol Geriatr; 1994; 18(3):161-8. PubMed ID: 15374296
    [TBL] [Abstract][Full Text] [Related]  

  • 93. EVALUTION OF UNILATERAL ELECTRO-CONVULSIVE THERAPY (A double blind study).
    Chatterjee SB; Mohammed E
    Indian J Psychiatry; 1980 Apr; 22(2):185-94. PubMed ID: 22058461
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Therapeutic and prophylactic role of cognitive enhancers in electroconvulsive therapy-induced cognitive deficits.
    Prakash J; Chaudhury S; Chatterjee K; Kotwal A; Srivastava K; Saha A
    Ind Psychiatry J; 2019; 28(2):286-293. PubMed ID: 33223724
    [TBL] [Abstract][Full Text] [Related]  

  • 95. CDP-choline for the treatment of tardive dyskinesia: a small negative series.
    Gelenberg AJ; Wojcik J; Falk WE; Bellinghausen B; Joseph AB
    Compr Psychiatry; 1989; 30(1):1-4. PubMed ID: 2647398
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial. Assessed by a new rating scale for recovery in hemiplegia.
    Hazama T; Hasegawa T; Ueda S; Sakuma A
    Int J Neurosci; 1980; 11(3):211-25. PubMed ID: 7002829
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [CDP choline in cerebral vasculopathy: clinical evaluation and instrumental semeiology].
    Corso EA; Arena M; Ventimiglia A; Bizzarro G; Campo G; Rodolico F
    Clin Ter; 1982 Aug; 102(4):379-86. PubMed ID: 6754218
    [No Abstract]   [Full Text] [Related]  

  • 98. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
    Fioravanti M; Yanagi M
    Cochrane Database Syst Rev; 2000; (2):CD000269. PubMed ID: 10796523
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The value of cytidine-5-diphosphate-choline in the prevention of impairment of memory function after electric convulsive therapy. A double-blind study.
    Ayuso-Gutierrez JL; Saiz-Ruiz J
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(3):243-8. PubMed ID: 6755560
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.